KW-0761 + Pralatrexate + gemcitabine plus oxaliplatin + DHAP
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adult T-cell Leukemia-Lymphoma
Conditions
Adult T-cell Leukemia-Lymphoma
Trial Timeline
Jun 1, 2012 → Feb 1, 2018
NCT ID
NCT01626664About KW-0761 + Pralatrexate + gemcitabine plus oxaliplatin + DHAP
KW-0761 + Pralatrexate + gemcitabine plus oxaliplatin + DHAP is a phase 2 stage product being developed by Kyowa Kirin for Adult T-cell Leukemia-Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01626664. Target conditions include Adult T-cell Leukemia-Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01626664 | Phase 2 | Completed |
Competing Products
20 competing products in Adult T-cell Leukemia-Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 + sotorasib | BridgeBio Pharma | Phase 1 | 30 |
| Daridorexant + Placebo | Idorsia | Phase 1 | 28 |
| SON-1010 (IL12-FHAB) | Sonnet BioTherapeutics | Phase 1 | 28 |
| Somatropin | Eli Lilly | Phase 3 | 77 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Pegilodecakin | Eli Lilly | Phase 1 | 33 |
| eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Lazertinib(G001) + Lazertinib(G002) | Yuhan | Phase 1 | 33 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |
| Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride | Eisai | Phase 1 | 33 |